Search the Newsreel

Why Liquidia Stock Was Diving This Week

Key Points The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug is doing well by any measure.10 stocks we like better than Liquidia › Liquidia(NASDAQ: LQDA) hasn't been the healthiest healthcare stock on the exchange over the past …

Liquidia (LQDA) Stock May Trade At A Premium On Earnings But A Discount On Broader Checks

Liquidia Corp (LQDA) Shares Fall 8.5% -- What GF Score of 70 Tells Investors

Liquidia Corp (LQDA) shares fell 8.5% to $72.10, yet GuruFocus's GF Value™ suggests it is significantly undervalued by 72.7% with a GF Score™ of 70. Despite strong growth potential, the company faces mixed signals from insider activity, including substantial insider selling, and concerns about …

Liquidia (NASDAQ:LQDA) Trading Down 6.6% Following Weak Earnings

Liquidia (NASDAQ:LQDA) experienced a 6.6% stock drop after reporting weaker-than-expected quarterly earnings, with an EPS of $0.74 missing the $0.76 consensus estimate. Despite this, revenue exceeded expectations at $171.68 million, an 1842.1% increase year-over-year, driven by strong sales of its drug YUTREPIA. Concerns remain …

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia Corporation (LQDA) reported strong second-quarter 2026 earnings, surpassing analyst estimates with EPS of 74 cents and total revenues of $171.7 million, primarily driven by robust sales of its lead drug, Yutrepia. Despite a 10% dip in shares post-announcement, the company's Yutrepia sales are …

Liquidia CEO Roger Jeffs Says Demand For Inhaled Lung Disease Drug Is Growing Amid Q2 Revenue Beat

Liquidia reported a strong second quarter, with total revenue of $171.7 million, exceeding Wall Street estimates, largely driven by sales of its inhaled lung disease drug, Yutrepia. Since its launch in June 2025, Yutrepia has received approximately 5,900 unique patient prescriptions and contributed significantly …

Liquidia: YUTREPIA Reaches 5,000+ Patients As Inhaled Prostacyclin Market Expands Nearly 40%

Liquidia's YUTREPIA has reached over 5,000 patients and generated $170.4 million in Q2 net product sales, contributing to a nearly 40% expansion of the inhaled prostacyclin market since its launch. The company has seen four consecutive quarters of increasing profitability and is pursuing a …

LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path

Liquidia Corporation's Q2 2026 earnings call emphasized the growth of YUTREPIA, aiming for over $1 billion in net revenue by 2027 through commercial expansion and increased adoption. The company reported strong Q2 financial results, with EPS and revenues exceeding consensus estimates, and plans to …

Liquidia (NASDAQ:LQDA) Price Target Raised to $92.00

Bank of America has raised its price target for Liquidia (NASDAQ:LQDA) to $92.00 from $79.00, maintaining a "neutral" rating, indicating a potential 16.77% upside. This comes despite Liquidia's recent quarterly earnings showing revenue growth of 1,842.1% year-over-year to $171.68 million and net income of …

Liquidia (LQDA) Turns Profitable In Q2, Is The Pullback A Valuation Opportunity?

Liquidia (LQDA) recently reported Q2 2026 results, shifting to profitability with increased revenue and positive net income, despite a recent share price pullback of over 10%. The company's stock has shown strong long-term performance, with a 212.66% return over the past year. Analysts see …

Needham & Company LLC Issues Positive Forecast for Liquidia (NASDAQ:LQDA) Stock Price

Needham & Company LLC has raised its price target for Liquidia (NASDAQ:LQDA) to $110 from $70, maintaining a "buy" rating and implying a 39% upside. Despite strong Q2 2026 revenue of $171.7 million and net income of $74.7 million, the stock fell 10.2% after …

Liquidia Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LQDA) 2026-08-12

Why No. 2 IBD 50 Stock, Liquidia, Dropped Despite Its Sales Beat

Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits. Continue Reading

Earnings call transcript: Liquidia misses EPS in Q2 2026 as YUTREPIA sales surge

Liquidia Corporation reported a Q2 2026 earnings miss with EPS of $0.74 against an estimated $0.76, but surpassed revenue expectations with $171.6

Liquidia Corp (NASDAQ:LQDA) Shows High Growth Momentum With a Breakout Setup

Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates

Liquidia Corp 2026: Revenue $171.68M, EPS $0.74— 10-Q Summary

Liquidia Corp reported strong financial results for the quarter ended 2026, with revenue reaching $171.68 million and diluted EPS of $0.74. This significant growth, representing an 1842.7% increase in revenue and 251% increase in diluted EPS year-over-year, was primarily driven by the successful commercial …

Liquidia Corporation Reports Second Quarter 2026 Financial Results

Liquidia Corporation reported strong financial results for the second quarter of 2026, driven by significant sales of its YUTREPIA inhalation powder, which generated approximately $170.4 million. The company achieved its fourth consecutive quarter of increasing profitability with a net income of $74.7 million and …

Liquidia earnings in focus as YUTREPIA launch faces patent test

Liquidia Technologies Inc. is reporting its second-quarter results with investors focusing on the commercial success of its new pulmonary hypertension drug, YUTREPIA, and the ongoing patent litigation. Analysts anticipate strong earnings and revenue growth, though the stock's recent surge reflects both high expectations and …

Sapient Capital LLC Has $1.83 Million Stake in Liquidia Corporation $LQDA

Sapient Capital LLC reduced its stake in Liquidia Corporation by 37.8% during the second quarter, now holding 23,000 shares valued at $1.83 million. Institutional investors collectively own 64.54% of Liquidia, while insiders sold approximately $125.8 million in stock, primarily due to tax obligations. Analysts …

Farallon Capital Management Trims Liquidia Corp (LQDA) Stake -- Shares Trade 45% Below GF Value

Farallon Capital Management reduced its stake in Liquidia Corp (LQDA) by 3.36%, selling 291,000 shares at $79.73 each. Despite Liquidia's significant year-to-date gain of 189.9% and its stock trading 45% below its GF Value, GuruFocus labels it a "Possible Value Trap," advising caution due …

Liquidia Corporation $LQDA Stock Holdings Lifted by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company significantly increased its stake in Liquidia Corporation (NASDAQ:LQDA) by 63.3% in the first quarter, now holding 58,265 shares valued at $2.2 million. Institutional investors collectively own 64.54% of Liquidia. Analysts maintain a "Moderate Buy" rating with an average price …

California State Teachers Retirement System Has $2.73 Million Stock Holdings in Liquidia Corporation $LQDA

The California State Teachers Retirement System increased its stake in Liquidia Corporation (NASDAQ:LQDA) by 25% to 72,438 shares, now valued at approximately $2.73 million. Institutional investors collectively own 64.54% of the company, which has received a consensus "Moderate Buy" rating from analysts with an …

Liquidia Corporation (NASDAQ:LQDA) Receives Average Rating of "Moderate Buy" from Brokerages

Liquidia Corporation (NASDAQ:LQDA) has received a "Moderate Buy" consensus rating from 11 brokerages, with an average 12-month price target of $86.18. The company recently surpassed quarterly earnings expectations, reporting $0.52 EPS against an anticipated $0.41, and revenue of $132.87 million, marking a significant year-over-year …

Is Liquidia (LQDA) Overvalued After Its Third Straight Profitable Quarter?

Liquidia (LQDA) has achieved its third consecutive profitable quarter, driven by demand for its pulmonary hypertension therapy YUTREPIA and a significant financing agreement. Despite a recent surge in share price, leading to it trading above the average analyst price target, valuation models show conflicting …

Liquidia Corporation (LQDA) Stock Forecasts

Liquidia Corp (LQDA) has received an Investment Rating of HOLD from Argus, with a target price raised to $93.00. The report details subratings for various financial aspects, categorizing the company's financial strength, growth, and value. Users can upgrade to premium services to access the …

Liquidia (NASDAQ:LQDA) Reaches New 1-Year High - Here's Why

Liquidia (NASDAQ:LQDA) reached a new 52-week high of $91.36, closing up 1.6% at $90.87, driven by positive analyst sentiment and strong quarterly earnings, where revenue surged over 4,000%. Despite this, company insiders sold approximately 2.18 million shares worth $143.9 million in the last 90 …

Zacks Investment Ideas feature highlights: Lenovo, Victoria's Secret and Liquidia

Zacks Investment Ideas highlights three top-ranked stocks: Lenovo Group, Victoria's Secret, and Liquidia Corp., all showing strong earnings momentum and positive price action. Lenovo is transforming into an AI hardware provider with significant revenue growth, Victoria's Secret is undergoing a successful brand turnaround with …

Farallon Group discloses 8.37M Liquidia (LQDA) shares, a 9.4% ownership stake

Farallon Capital Management, L.L.C. and related entities have disclosed an 8.37 million share beneficial ownership stake in Liquidia Corporation (LQDA), representing 9.4% of the company's outstanding common stock. This information was filed via an amended Schedule 13G/A, indicating shared voting and dispositive power over …

Is Liquidia (LQDA) Stock Too Rich After A 35x Run?

Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?

Liquidia Corporation (LQDA) is set to release its Q2 earnings on August 12, with strong sales and EPS estimates. The company has a positive earnings surprise history and its Yutrepia inhalation powder is a key growth driver, with impressive adoption rates. Despite competition, especially …

Liquidia Corp (LQDA) Institutional Confidence

Liquidia Corp (LQDA) has an institutional shareholding score of 7.00, ranking 50 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 73.52%, showing a quarter-over-quarter increase of 0.02%. Farallon Capital Management, L.L.C. is a significant institutional shareholder, holding 8.66 million …

LQDA|Liquidia Corp|Price:86.870|Chg%:+0.050

This article provides a detailed financial overview of Liquidia Corp (LQDA), including its stock performance, key financial indicators like EPS, revenue, net profit, and gross margin across various quarters and fiscal years. It also presents the company's balance sheet and cash flow statement data, …